US based pharmaceuticals company Pfizer Inc. has this week announced a massive new acquisition plan.
The company has stated that it plans to buy Medivation, a fellow pharmaceuticals company, in order to strengthen its offerings in oncology. All up, the deal will be worth approximately $14bn, with Pfizer buying Medivation at a price of $81.50 per share. According to a press release, the company’s board has unanimously approved the purchase which…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
